Glaukos Corp (GKOS)

NYSE
Currency in USD
160.22
-1.00(-0.62%)
Closed
After Hours
161.71+1.49(+0.93%)
GKOS Scorecard
Full Analysis
Analysts do not anticipate the company will be profitable this year
Fair Value
Day's Range
158.29161.33
52 wk Range
83.90163.71
Key Statistics
Edit
Prev. Close
161.22
Open
159.43
Day's Range
158.29-161.33
52 wk Range
83.9-163.71
Volume
369.74K
Average Vol. (3m)
592.54K
1-Year Change
73.17%
Book Value / Share
12.17
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
GKOS Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
155.25
Downside
-3.10%
Members' Sentiments
Bearish
Bullish
ProTips
High return over the last year
Show more

Glaukos Corp Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Compare GKOS to Peers and Sector

Metrics to compare
GKOS
Peers
Sector
Relationship
P/E Ratio
−59.0x−4.6x−0.7x
PEG Ratio
6.55−0.060.00
Price / Book
13.2x1.7x2.6x
Price / LTM Sales
24.5x3.4x3.1x
Upside (Analyst Target)
−1.1%39.2%49.0%
Fair Value Upside
Unlock−4.2%7.4%Unlock

Analyst Ratings

11 Buy
2 Hold
1 Sell
Ratings:
14 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 155.25
(-3.10% Downside)

Earnings

Latest Release
Nov 04, 2024
EPS / Forecast
-0.28 / -0.48
Revenue / Forecast
96.70M / 91.50M
EPS Revisions
Last 90 days

People Also Watch

57.44
VERX
+0.77%
55.000
VRNA
+1.70%
44.31
VRNS
+0.07%
32.57
NCNO
+0.18%
55.77
HALO
+0.25%

FAQ

What Is the Glaukos Corp (GKOS) Stock Price Today?

The Glaukos Corp stock price today is 160.22

What Stock Exchange Does Glaukos Corp Trade On?

Glaukos Corp is listed and trades on the NYSE stock exchange.

What Is the Stock Symbol for Glaukos Corp?

The stock symbol for Glaukos Corp is "GKOS."

What Is the Glaukos Corp Market Cap?

As of today, Glaukos Corp market cap is 8.83B.

What is Glaukos Corp Earnings Per Share?

The Glaukos Corp EPS is -2.93.

What Is the Next Glaukos Corp Earnings Date?

Glaukos Corp will release its next earnings report on Feb 19, 2025.

From a Technical Analysis Perspective, Is GKOS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.